MedPath

PrediCT - Predisposition to Childhood Tumors

Not Applicable
Completed
Conditions
<p>Pediatric cancer/neoplasms</p>
10068775
Registration Number
NL-OMON20548
Lead Sponsor
Princes Máxima Center for pediatric oncology
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
843
Inclusion Criteria

- Children (age < 19 years) newly diagnosed with cancer or neoplasms at the Princess Máxima Center - Written informed consent (by patient when aged 16 years or older, by patient and parent(s) when aged 12-16 years, by parent(s) when younger than 12 years)

Exclusion Criteria

- Patients and/or their parents who don't want to know the results of the DNA test (pediatric cancer gene panel analysis)

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Endpoint of this study is determining the performance of a ‘genotype first approach’ in diagnostics of genetic predisposition in children with cancer (unselected for type of tumor), compared to the current ‘phenotype first approach’. We will evaluate the number of identified pediatric cancer predisposition syndromes (CPSs) by the genotype first approach and the phenotype first approach and will focus on discrepancies in diagnoses between these two approaches. Pediatric cancer predisposition syndromes are defined as clinical diagnosis (made by a clinical geneticist) and/or molecular diagnosis (based on targeted tests or WES CPS panel).</p><br>
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath